共 113 条
[1]
Esfahani K(2020)A review of cancer immunotherapy: from the past, to the present, to the future Curr Oncol 27 S87-287
[2]
Roudaia L(2016)Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy Nat Rev Cancer 16 275-264
[3]
Buhlaiga N(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-473
[4]
Del Rincon SV(2016)PD-1/PD-L1 blockade in cancer treatment: perspectives and issues Int J Clin Oncol 21 462-383
[5]
Papneja N(2018)Inhibitors of the PD-1 pathway in tumor therapy J Immunol 200 375-11
[6]
Miller WH(2019)Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors J Immunother Cancer 7 1-21
[7]
Topalian SL(2020)Immune-related adverse events of checkpoint inhibitors Nat Rev Dis Primer 6 1-2391
[8]
Taube JM(2015)Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies Ann Oncol 26 2375-1304
[9]
Anders RA(2018)Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma Clin Cancer Res 24 1296-545
[10]
Pardoll DM(2018)Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study Br J Cancer 119 538-127